Article
Distribution and prognostic value of histopathologic data and immunohistochemical markers in gastrointestinal stromal tumours (GISTs): An analysis of the EORTC phase III trial of treatment of metastatic GISTs with imatinib mesylate.
European journal of cancer (Oxford, England : 1990) - 1 Sept 2008
Sciot Raf, Debiec-Rychter Maria, Daugaard Soren, Fisher Cyril, Collin Francoise, van Glabbeke Martine, Verweij Jaap, Blay Jean-Yves, Hogendoorn Pancras C W
Abstract excerpt
RATIONALE: The 62005 EORTC phase III trial, comparing two doses of imatinib in patients with advanced GIST, reported a median progression-free survival of 25 months with a trend towards dose dependency for progression-free survival. The current analysis of that study aimed to assess whether histological/immunohistochemical parameters correlate with clinical response to imatinib. PATIENTS AND METHODS:...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.